Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab
Status:
Active, not recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
Was to demonstrate superiority of secukinumab compared to placebo in patients with moderate
to severe chronic palmoplantar pustular psoriasis with respect to the palmoplantar
pustulosis Psoriasis Area and Severity Index 75 response rate